Some immunotherapy drugs target the PD-L1 protein, though this expert says that it is still an imperfect biomarker.
H. Jack West, M.D.
Advertisement
Articles by H. Jack West, M.D.
Advertisement
Latest Updated Articles
PD-L1: An Important, But Imperfect BiomarkerPublished: June 11th 2018 | Updated:
Advertisement
Advertisement
Trending on CURE
1
What Newly Diagnosed Patients Need to Know About Stage 2 Melanoma
2
Survivorship and the Power of Community in Breast Cancer Awareness
3
Finding Hope Amidst a Lung Cancer Diagnosis
4
FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue Sarcoma
5
